Cellbxhealth Expands Parsortix Platform Partnership with Pharmaceutical Company in US

03:16 AM EDT, 10/14/2026 (MT Newswires) -- Cellbxhealth (CLBX.L) signed a new statement of work worth $65,000 under a master services agreement, expanding its partnership with an unnamed US-based pharmaceutical company. Under the agreement, the British circulating tumor cell intelligence company will process 100 patient samples through its Parsortix platform for isolation and harvesting of circulating tumor cells for downstream molecular analysis, according to a Wednesday filing.